Taupe needle crystal
seeds of Sesamum indicum
5-Benzodioxolol/5-Hydroxy-1,3-benzodioxole/Phenol, 3,4- (methylenedioxy)-/Sesamol/4,5-methylenedioxyphenol/3,4-Methylenedioxyphenol/1-hydroxy-3,4-methylenedioxybenzene/4-hydroxy-1,2-methylenedioxy-benzene/5-hydroxy-1,3-benzodioxolane/3,4-(Methylenedioxy)phenol/Methylene ether of oxyhydroquinone/1,3-benzodioxol-5-ol
274.0±29.0 °C at 760 mmHg
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:533-31-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
To evaluate the effects of topically and subconjunctivally administered sesamol on experimentally induced corneal neovascularization in rats.
Fifty-six right eyes of 56 Wistar Albino rats were chemically cauterized to induce corneal neovascularization in this experimental and comparative study. The subjects were divided into eight groups: topical sesamol (group 1), subconjunctival sesamol (group 2), topical bevacizumab (group 3), subconjunctival bevacizumab (group 4), topical bevacizumab+ sesamol (group 5), subconjunctival bevacizumab+ sesamol (group 6), topical Tween 80 (group 7), and control (group 8). The amount of subconjunctivally injected sesamol and bevacizumab was 1.25 mg each. Topical groups were administered 10 mg/mL drops twice daily. The control group was left untreated. To evaluate the degree of corneal neovascularization, digital photographs and corneal sections stained with hematoxylin-eosin and CD31 were used.
When photographs of neovascularization areas were examined, all treatment groups showed statistically significant differences when compared with the control group (P<0.001). Topical sesamol was found to be more effective when compared with subconjunctival sesamol (P=0.003). Topical sesamol+ bevacizumab was found to be more effective when compared with topical bevacizumab (P=0.018). The numbers of new corneal vessels were as follows: 12.28±6.29 in group 1, 36.85±12.8 in group 2, 18.85±7.71 in group 3, 16.85±8.70 in group 4, 19.57±8.56 in group 5, 22.57±7.43 in group 6, 45.00±11.29 in group 7, and 51.16±5.91 in group 8 (P<0.001).
The outcomes of this study suggest antiangiogenic effects of sesamol. The use of topical sesamol monotherapy or sesamol combined with bevacizumab may be options for the prevention of corneal neovascularization.
Is Sesamol Effective in Corneal Neovascularization?
Kaya H1, Pekel G, Yorukoglu A, Hiraali MC, Sahin B.
Sesamol is a natural phenolic compound and a major lignan isolated from sesame seeds (Sesamum indicum) and sesame oil. The therapeutic potential of sesamol was investigated intensively, and there is compelling evidence that sesamol acts as a metabolic regulator that possesses antioxidant, anti-mutagenic, anti-hepatotoxic, anti-inflammatory, anti-aging, and chemopreventive properties. Various studies have reported that sesamol exerts potent anti-cancer effects. Herein, we provide a comprehensive review that summarizes the in vitro and in vivo anti-cancer activity of sesamol in several cancer cell lines and animal models. The protective role that sesamol plays against oxidative stress through its radical scavenging ability and lipid peroxidation lowering potential is analyzed. The ability of sesamol to regulate apoptosis and various stages of the cell cycle is also outlined. Moreover, the signaling pathways that sesamol seems to target to execute its antioxidant, anti-inflammatory, and pro-apoptotic/anti-proliferative roles are discussed. The signaling pathways that sesamol targets include the p53, MAPK, JNK, PI3K/AKT, TNFα, NF-κB, PPARγ, caspase-3, Nrf2, eNOS, and LOX pathways. The mechanisms of action that sesamol executes to deliver its anti-cancer effects are delineated. In sum, there is ample evidence suggesting that sesamol possesses potent anti-cancer properties in vitro and in vivo. A thorough understanding of the molecular targets of sesamol and the mechanisms of action underlying its anti-cancer effects is necessary for possible employment of sesamol as a chemotherapeutic agent in cancer prevention and therapy.
Copyright © 2019 Elsevier B.V. All rights reserved.
Anti-cancer; Antioxidant; Apoptosis; Inflammation; Sesamol; Sesamum indicum
Sesamol, a major lignan in sesame seeds (Sesamum indicum): Anti-cancer properties and mechanisms of action.
Majdalawieh AF1, Mansour ZR2.
2019 Jul 15
Oxidative stress is considered as a pivotal culprit in neurodegenerative diseases and brain aging. The aim of present study was to investigate antioxidative and neuroprotective effects of sesamol, a phenolic lignan from sesame oil, on oxidative stress induced neuron damage and memory impairments. C57BL/6J mice were treated by intraperitoneal injections of d-galactose for 8 weeks. Sesamol treatment (0.05% w/v, in drinking water) suppressed d-galactose-induced liver damages and improved HO-1 and NQO1 mRNA levels. Behavioral tests, including Y-maze test and water maze-test, revealed that sesamol significantly improved oxidative stress-induced cognitive impairments. Meanwhile, sesamol ameliorated neuronal damage and improved BDNF level in rat hippocampus. Sesamol elevated mRNA levels and protein expressions of antioxidant enzymes HO-1 and NQO1 as well as decreased inflammatory cytokines TNF-α and IL-1β in d-galactose-treated mice serum. In addition, activity of CAT and GSH level were increased in sesamol-treated mice serum. Moreover, sesamol treatment also balanced cellular redox status, protected mitochondrial dysfunction and upregulated antioxidant enzymes by activating the Nrf2 transcriptional pathway and its nuclear translocation in H2O2-treated SH-SY5Y cells. In conclusion, these results revealed that sesamol could be a potential neuroprotective agent during aging process due to its beneficial effects on liver-brain axis.
Protective effects of sesamol on systemic oxidative stress-induced cognitive impairments via regulation of Nrf2/Keap1 pathway.
Ren B 1, Yuan T , Diao Z , Zhang C , Liu Z , Liu X .
2018 Nov 14